HC Wainwright reiterated their neutral rating on shares of Cassava Sciences (NASDAQ:SAVA - Free Report) in a research note released on Tuesday,Benzinga reports. HC Wainwright also issued estimates for Cassava Sciences' FY2025 earnings at ($0.55) EPS.
Cassava Sciences Stock Down 0.4 %
Shares of NASDAQ SAVA traded down $0.01 during trading on Tuesday, hitting $2.81. 1,600,199 shares of the company traded hands, compared to its average volume of 2,861,314. Cassava Sciences has a 1 year low of $2.23 and a 1 year high of $42.20. The company has a 50-day moving average price of $2.56 and a 200-day moving average price of $14.65. The firm has a market capitalization of $135.19 million, a P/E ratio of -2.04 and a beta of -1.24.
Cassava Sciences (NASDAQ:SAVA - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.11. Research analysts predict that Cassava Sciences will post -3.97 EPS for the current fiscal year.
Institutional Trading of Cassava Sciences
Institutional investors have recently made changes to their positions in the stock. KBC Group NV purchased a new stake in shares of Cassava Sciences during the 3rd quarter valued at $57,000. Quest Partners LLC boosted its position in Cassava Sciences by 117.8% during the 3rd quarter. Quest Partners LLC now owns 1,997 shares of the company's stock worth $59,000 after purchasing an additional 1,080 shares during the period. Creative Planning purchased a new stake in Cassava Sciences during the 3rd quarter worth $201,000. Independent Advisor Alliance purchased a new stake in Cassava Sciences during the 3rd quarter worth $208,000. Finally, BNP Paribas Financial Markets boosted its position in Cassava Sciences by 150.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,748 shares of the company's stock worth $257,000 after purchasing an additional 5,250 shares during the period. 38.05% of the stock is owned by hedge funds and other institutional investors.
About Cassava Sciences
(
Get Free Report)
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Featured Stories
Before you consider Cassava Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.
While Cassava Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
